The chorioallantoic membrane as a bio-barrier model for the evaluation of nanoscale drug delivery systems for tumour therapy
E Preis, J Schulze, B Gutberlet, SR Pinnapireddy… - Advanced drug delivery …, 2021 - Elsevier
Abstract In 2010, the European Parliament and the European Union adopted a directive on
the protection of animals used for scientific purposes. The directive aims to protect animals …
the protection of animals used for scientific purposes. The directive aims to protect animals …
From resistance to sensitivity: insights and implications of biphasic modulation of autophagy by sunitinib
Sunitinib, a multityrosine kinase inhibitor, is currently the standard first-line therapy in
metastatic renal cell carcinoma (mRCC) and is also used in treating patients with pancreatic …
metastatic renal cell carcinoma (mRCC) and is also used in treating patients with pancreatic …
Autophagy inhibition improves sunitinib efficacy in pancreatic neuroendocrine tumors via a lysosome-dependent mechanism
T Wiedmer, A Blank, S Pantasis, L Normand… - Molecular cancer …, 2017 - AACR
Increasing the efficacy of approved systemic treatments in metastasized pancreatic
neuroendocrine tumors (PanNET) is an unmet medical need. The antiangiogenic tyrosine …
neuroendocrine tumors (PanNET) is an unmet medical need. The antiangiogenic tyrosine …
Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations
GA Patwardhan, M Marczyk, VB Wali, DF Stern… - NPJ Breast …, 2021 - nature.com
The effect of scheduling of targeted therapy combinations on drug resistance is
underexplored in triple-negative breast cancer (TNBC). TNBC constitutes heterogeneous …
underexplored in triple-negative breast cancer (TNBC). TNBC constitutes heterogeneous …
Molecular and functional analysis of sunitinib-resistance induction in human renal cell carcinoma cells
Resistance in clear cell renal cell carcinoma (ccRCC) against sunitinib is a multifaceted
process encompassing numerous molecular aberrations. This induces clinical …
process encompassing numerous molecular aberrations. This induces clinical …
Proteomic analysis of miR-195 and miR-497 replacement reveals potential candidates that increase sensitivity to oxaliplatin in MSI/P53wt colorectal cancer cells
Most patients with advanced colorectal cancer (CRC) eventually develop resistance to
systemic combination therapy. miR-195-5p and miR-497-5p are downregulated in CRC …
systemic combination therapy. miR-195-5p and miR-497-5p are downregulated in CRC …
High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors
Simple Summary Multitargeted tyrosine kinase inhibitors (TKIs) provide clinical benefit in
patients with cancer when daily dosed to continuously inhibit their designated targets …
patients with cancer when daily dosed to continuously inhibit their designated targets …
Phase I dose-escalation study of once weekly or once every two weeks administration of high-dose sunitinib in patients with refractory solid tumors
M Rovithi, SL Gerritse, RJ Honeywell… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Dose and schedule optimization of treatment with tyrosine kinase inhibitors is of
utmost importance. On the basis of preclinical data, a phase I clinical trial of once weekly or …
utmost importance. On the basis of preclinical data, a phase I clinical trial of once weekly or …
Tyrosine kinase inhibitor pazopanib inhibits platelet procoagulant activity in renal cell carcinoma patients
BME Tullemans, M Nagy, S Sabrkhany… - … and Vascular Medicine, 2018 - frontiersin.org
Pazopanib is an angiostatic tyrosine kinase inhibitor (TKI) presently used for cancer
treatment, particularly in patients with renal cell carcinoma (RCC). This treatment can be …
treatment, particularly in patients with renal cell carcinoma (RCC). This treatment can be …
High-dose short-term osimertinib treatment is effective in patient-derived metastatic colorectal cancer organoids
KK Iyer, D Poel, A Miggelenbrink, W Kerkhof, J Janssen… - BJC Reports, 2024 - nature.com
Background Most tyrosine kinase inhibitors (TKIs) have failed in clinical trials for metastatic
colorectal cancer (mCRC). To leverage the additional lower-affinity targets that most TKIs …
colorectal cancer (mCRC). To leverage the additional lower-affinity targets that most TKIs …